Drug Profile
Sifalimumab
Alternative Names: Anti-IFNa MAb; MDX-1103; MEDI-545Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Medarex
- Developer MedImmune
- Class Monoclonal antibodies
- Mechanism of Action Interferon alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myositis; Psoriasis; Systemic lupus erythematosus
Most Recent Events
- 19 Jul 2016 MedImmune completes its phase II trial for Systemic lupus erythematosus in Japan (NCT01031836)
- 31 Mar 2015 Discontinued - Phase-II for Systemic lupus erythematosus in USA and Japan (SC)
- 31 Mar 2015 Discontinued - Phase-II for Systemic lupus erythematosus in USA, Argentina, Brazil, Bulgaria, Canada, Chile, Colombia, France, Germany, Hungary, India, Italy, Jamaica, Japan, Mexico, Netherlands, Peru, Philippines, Poland, Romania, South Africa, Spain, Thailand and United Kingdom (IV)